公开(公告)号：US20240350644A1

公开(公告)日：2024-10-24

申请号：US18670931

申请日：2024-05-22

申请人： Der-Yang TIEN

发明人： Der-Yang TIEN

IPC分类号： A61K47/59 ,  A61K31/05 ,  A61K31/165 ,  A61K31/337 ,  A61K31/352 ,  A61K31/353 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/4412 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/537 ,  A61K31/5513 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/243 ,  A61K47/60 ,  A61P35/00

CPC分类号： A61K47/593 ,  A61K31/05 ,  A61K31/165 ,  A61K31/337 ,  A61K31/352 ,  A61K31/353 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/4412 ,  A61K31/4418 ,  A61K31/496 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/537 ,  A61K31/5513 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/243 ,  A61K47/60 ,  A61P35/00

摘要： Disclosed herein are stereocomplexes for the delivery of one or more anti-cancer agents. The stereocomplexes exhibit low toxicity and are biodegradable while also providing for controlled release of one or more anti-cancer agents at tumor sites. The stereocomplexes can be designed such that the anti-cancer agents operate synergistically and may optionally include additional targeting groups and functionalities. The stereocomplexes disclosed herein can be combined with pharmaceutically-acceptable carriers and/or excipients to form pharmaceutical compositions. By varying the amount of each anti-cancer agent in the stereocomplex, specific types of tumors and cancer cell lines can be treated.

公开(公告)号：US20240335416A1

公开(公告)日：2024-10-10

申请号：US18626002

申请日：2024-04-03

申请人： PhenoNet, Inc.

发明人： David R. ELMALEH

IPC分类号： A61K31/352 ,  A61K31/192

CPC分类号： A61K31/352 ,  A61K31/192

摘要： The present disclosure provides methods of treatment of neurodegenerative disease in subjects in need thereof. A therapeutically effective dose of combination of a suitable mast cell stabilizer and NSAID may be administered to suitable subjects, wherein the suitability of a subject is determined by subject genotype. In certain embodiments, the combination therapy may comprise a combination of a cromolyn homolog salt and an NSAID, and suitable subjects are persons who are not carriers APOE ε4 variant of the APOE gene.

公开(公告)号：US12109189B2

公开(公告)日：2024-10-08

申请号：US18138351

申请日：2023-04-24

申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

发明人： Mark G. Frattini ,  Hakim Djaballah ,  Thomas J. Kelly

IPC分类号： A61K31/365 ,  A61K9/00 ,  A61K31/122 ,  A61K31/352 ,  A61N5/10 ,  C07D493/08 ,  C07D493/18 ,  C09B13/02 ,  C09B61/00 ,  C12Q1/6886

CPC分类号： A61K31/365 ,  A61K9/0019 ,  A61K31/122 ,  A61K31/352 ,  A61N5/10 ,  C07D493/08 ,  C07D493/18 ,  C09B13/02 ,  C09B61/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

摘要： The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B):




or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.

公开(公告)号：US20240325414A1

公开(公告)日：2024-10-03

申请号：US18579985

申请日：2022-07-21

申请人： Nicoventures Trading Limited

发明人： Steven ALDERMAN ,  Thomas POOLE ,  Michael DANIEL ,  Kai TANG ,  Keyi XU ,  Karina MCQUILLAN

IPC分类号： A61K31/00 ,  A61K31/01 ,  A61K31/352 ,  A61K45/06

CPC分类号： A61K31/658 ,  A61K31/01 ,  A61K31/352 ,  A61K45/06

摘要： The present invention relates to compositions comprising a constituent, derivative or extract of Cannabis in a water soluble matrix. The invention also relates to uses of such compositions and methods of manufacturing them.

公开(公告)号：US20240325345A1

公开(公告)日：2024-10-03

申请号：US18625198

申请日：2024-04-02

申请人： david alan heldreth, JR.

发明人： david alan heldreth, JR.

IPC分类号： A61K31/352 ,  A61K31/015 ,  A61K31/05 ,  A61K31/135 ,  A61K31/164 ,  A61K31/165 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/48 ,  A61K31/675 ,  A61K31/704 ,  A61K33/06 ,  A61K33/30 ,  A61K36/68 ,  A61K36/77

CPC分类号： A61K31/352 ,  A61K31/015 ,  A61K31/05 ,  A61K31/135 ,  A61K31/164 ,  A61K31/165 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/48 ,  A61K31/675 ,  A61K31/704 ,  A61K33/06 ,  A61K33/30 ,  A61K36/68 ,  A61K36/77

摘要： The invention involves the use of formulations of allosteric modulators of primarily 5ht2/tht1, CB1, serotonin transporter and opiate receptors/systems, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, and other receptors, used before, after or in combination with phenethylamines, tryptamines, ibogaloids and other compounds; to increase the effects of ingestion of drugs such as Cannabis or 5-ht2a agonists. The method of delivery/formulation selected from: Beverage (soda, water, tea, coffee, or other), Candy (gum, gummy, chocolate, hard candy, taffy, or other), Food, smoking, vaping, e-cigarette, vape-pen, bong, vaporizer.

公开(公告)号：US20240325343A1

公开(公告)日：2024-10-03

申请号：US18625187

申请日：2024-04-02

申请人： david alan heldreth, JR.

发明人： david alan heldreth, JR.

IPC分类号： A61K31/352 ,  A61K31/015 ,  A61K31/05 ,  A61K31/135 ,  A61K31/164 ,  A61K31/165 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/48 ,  A61K31/675 ,  A61K31/704 ,  A61K33/06 ,  A61K33/30 ,  A61K36/68 ,  A61K36/77

CPC分类号： A61K31/352 ,  A61K31/015 ,  A61K31/05 ,  A61K31/135 ,  A61K31/164 ,  A61K31/165 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/48 ,  A61K31/675 ,  A61K31/704 ,  A61K33/06 ,  A61K33/30 ,  A61K36/68 ,  A61K36/77

摘要： The invention involves the use of formulations of allosteric modulators of primarily 5ht2/tht1, CB1 and GLP-1 serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7 and other receptors, in combination with vaccines/antibodies, and phenethylamines, tryptamines, ibogaloids and other compounds; to treat or reduce symptoms of ingestion of drugs such as cannabis or 5-ht2a agonists. The method of delivery/formulation selected from: Inhaler, nebulizer, intravenously, intramuscularly, injection, capsules, tablets, pills.

公开(公告)号：US20240325340A1

公开(公告)日：2024-10-03

申请号：US18292464

申请日：2022-07-27

申请人： Thomas Jefferson University ,  Texas Heart Institute

发明人： Roger S. Armen ,  Tung Chan ,  Ulrich Rodeck ,  Richard A. F. Dxon ,  Ronald J. Biediger

IPC分类号： A61K31/352 ,  A61K31/165 ,  A61K31/433 ,  C07D311/04

CPC分类号： A61K31/352 ,  A61K31/165 ,  A61K31/433 ,  C07D311/04

摘要： The invention relates in one aspect to compounds, pharmaceutical compositions thereof, and methods using the same for selectively activating either all or a single isoform of Akt. Isoform selective-targeting is necessary for avoiding pathologies driven by concomitantly activated Akt1, Akt2 and/or Akt3.

公开(公告)号：US12097235B2

公开(公告)日：2024-09-24

申请号：US17312608

申请日：2019-12-10

申请人： UNIVERSITY OF PRETORIA

发明人： Isa Anina Lambrechts ,  Namrita Lall

IPC分类号： A61K36/53 ,  A61K9/06 ,  A61K31/352 ,  A61K47/10 ,  A61K47/14 ,  A61K47/18 ,  A61K47/32 ,  A61P17/10

CPC分类号： A61K36/53 ,  A61K9/06 ,  A61K31/352 ,  A61K47/10 ,  A61K47/14 ,  A61K47/18 ,  A61K47/183 ,  A61K47/32 ,  A61P17/10 ,  A61K2236/331 ,  A61K2236/333

摘要： The invention provides a pharmaceutical composition suitable for topical application. The pharmaceutical composition comprises an extract of Plectranthus aliciae and a pharmaceutically acceptable carrier. The invention extends to provide a pharmaceutical composition for the treatment of acne, a pharmaceutical gel composition, a substance or composition comprising an extract of Plectranthus aliciae, a use of a Plectranthus aliciae extract, and various methods of preventing or treating acne.

公开(公告)号：US20240307320A1

公开(公告)日：2024-09-19

申请号：US18577088

申请日：2022-07-08

申请人： Biophagy, Inc.

发明人： Mary Ortner ,  Stuart Rose ,  Ian Henderson

IPC分类号： A61K31/05 ,  A61B10/02 ,  A61K31/12 ,  A61K31/132 ,  A61K31/192 ,  A61K31/352 ,  A61K31/4412 ,  A61K31/7016

CPC分类号： A61K31/05 ,  A61B10/02 ,  A61K31/12 ,  A61K31/132 ,  A61K31/192 ,  A61K31/352 ,  A61K31/4412 ,  A61K31/7016 ,  A61B2010/0216

摘要： A system for stimulating autophagy comprising a sample collection kit (either a buccal swab kit or a lancet kit) and one or more compounds that stimulate autophagy. The buccal swab kit has at least one buccal swab, a collection container, a storage device, a shipping package, a set of instructions, and at least one set of gloves. The lancet kit has at least one sterile lancet or an automated lancet device for capillary bloodletting, a sealed packet with an isopropyl alcohol wipe or pad, a collection container, a storage device, and a shipping package. A method of stimulating autophagy in an individual comprising the steps of providing the individual with at least one sample collection kit, testing the sample provided by the individual to determine the individual's level of autophagy, and administering one or more compounds to the individual to stimulate autophagy on a single use or subscription basis.

公开(公告)号：US20240299470A1

公开(公告)日：2024-09-12

申请号：US18262629

申请日：2022-01-25

申请人： SEED HEALTH INC.

发明人： Rajat DHIR ,  Gregor REID ,  Ara KATZ

IPC分类号： A61K35/744 ,  A61K9/00 ,  A61K9/48 ,  A61K31/352 ,  A61K36/185

CPC分类号： A61K35/744 ,  A61K9/0053 ,  A61K9/4808 ,  A61K31/352 ,  A61K36/185

摘要： Synbiotic compositions including both a prebiotic component and a probiotic component are provided. The prebiotic component includes at least one punicalagin, and the probiotic component includes a rationally defined and assembled consortium of microbial strains. Delivery capsules for oral administration of the synbiotic compositions and methods of using the synbiotic compositions to treat disease are also provided.